# Oral Semaglutide in Patients With Alzheimer's Disease

> **NCT07200622** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Imperial College London** · enrollment: 60 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Semaglutide (Rybelsus®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07200622
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200622, "Oral Semaglutide in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07200622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*